Candel Therapeutics Prices $100M Share Offering To Fund Aglatimagene Development

Candel Therapeutics, Inc. (CADL) has announced the successful pricing of its public share offering, setting the stage for significant advancement in its immunotherapy pipeline. The clinical-stage biopharmaceutical company priced 18.35 million common shares at $5.45 per share, generating $100 million in gross proceeds to accelerate development and commercialization efforts for its lead oncology asset.

Share Offering Details and Market Response

Candel’s financing round represents a strategic capital raise to support critical near-term objectives. The offering is structured to include 18.35 million shares at the $5.45 price point, with underwriters granted a 30-day option to purchase an additional 2.75 million shares worth $15 million under identical terms. The transaction is projected to close by late February 2026. Major financial institutions—Citigroup, Cantor Fitzgerald, and Stifel—serve as joint bookrunning managers, while LifeSci Capital leads the placement. Following the pricing announcement, CADL shares declined to $5.25, reflecting an 11.76% pullback. Historically, the stock has fluctuated between $4.25 and $13.68, with recent trading activity showing modest volatility in the broader biotech sector.

Aglatimagene: Multi-Indication Oncology Candidate

The capital raised will primarily support aglatimagene besadenovec (CAN-2409), Candel’s flagship therapeutic candidate targeting multiple cancer indications. The company plans to deploy proceeds toward launch readiness activities, medical affairs infrastructure, and pre-commercialization planning for aglatimagene’s primary indication—early-stage, localized prostate cancer. Importantly, the funding will also accelerate ongoing Phase 3 development in non-small cell lung cancer (NSCLC) and support general corporate operations. This multi-pronged approach positions aglatimagene for comprehensive market penetration across multiple malignancies.

Clinical Progress and Regulatory Recognition

Candel has achieved substantial clinical validation across its pipeline. The company recently completed successful Phase 2a studies of aglatimagene in both NSCLC and pancreatic ductal adenocarcinoma (PDAC), demonstrating therapeutic potential in difficult-to-treat cancers. Most notably, a placebo-controlled Phase 3 trial in localized prostate cancer has been successfully completed, positioning the asset for regulatory submission. Beyond aglatimagene, Candel’s second platform candidate, Linoserpaturev, is progressing through Phase 1b evaluation in recurrent high-grade glioma, expanding the company’s reach into CNS malignancies.

The FDA has recognized aglatimagene’s potential through multiple designations, including Fast Track status for both NSCLC and PDAC indications, alongside Orphan Drug Designation for PDAC. Additionally, the agency granted both Fast Track Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation for newly diagnosed, localized prostate cancer in intermediate- to high-risk patient populations—a critical endorsement that can accelerate regulatory timelines.

Candel’s Dual-Platform Innovation Strategy

Candel’s competitive positioning rests on two distinct immunotherapy platforms built on genetically modified viral constructs. The adenovirus-based platform has yielded aglatimagene, while a complementary herpes simplex virus (HSV) platform generated Linoserpaturev. This diversified approach mitigates single-asset risk and provides multiple pathways to establish market presence across oncology. The funding secured through this offering enables Candel to simultaneously advance both clinical programs while building commercial infrastructure for potential near-term approvals and launches.